Ticagrelor, a potent inhibitor of P2Y12 platelet receptor, co-administered with aspirin in dual antiplatelet therapy (DAPT), received marketing authorization from the European Medicines Agency in December 2010 and by the Food and Drug Administration in July 2011 for the prevention of atherothrombotic events in adult patients with acute coronary syndromes (ACS) . The basis for the approval was the PLATO trial, a randomized controlled study in ACS patients, showing that DAPT with ticagrelor reduced a composite endpoint of cardiovascular death, myocardial infarction (MI) or stroke at 12 months as compared to clopidogrel [1].
